Report Highlights Nexalin's Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment

HOUSTON, TX, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") announces that its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology is prominently featured in a newly published editorial in Psychotherapy and Psychosomatics. This peer-reviewed article provides compelling validation of Nexalin's ability to non-invasively treat challenging psychiatric conditions, highlighting the Company's unique positioning in the rapidly growing neuromodulation market, which is projected to reach $11.0 billion by 2028.

The editorial underscores the advantages of the Company's 15mA DIFS over traditional neurostimulation and neuromodulation devices. Unlike low-intensity transcranial alternating current stimulation (tACS) or low-intensity transcranial direct current stimulation (tDCS), which lack sufficient power to reach deeper brain regions, Nexalin's technology delivers high-intensity frequency-based stimulation capable of activating critical areas such as the hippocampus, amygdala, and insula. Supported by stereoelectroencephalography (SEEG) recordings, the findings described in the editorial support the Company's ability to address previously unmet needs in treating conditions like major depressive disorder (MDD), chronic insomnia and other mental health issues.

"This publication provides robust validation of Nexalin's technology from a scientific perspective and reinforces the Company's ability to address significant gaps in the mental health market," said Dr. David Owens, Chief Medical Officer at Nexalin Technology. "By effectively reaching deep brain regions non-invasively, Nexalin's DIFS technology has the potential to become a cornerstone in treatment paradigms for psychiatric disorders."

Key insights from the publication include:

• Deep Brain Penetration: Unlike traditional devices, the Company's 15mA DIFS achieves significant activation of deep brain regions critical for mental health treatment, far surpassing the reach of low-intensity devices.
• Tailored Neuromodulation: The article validates that different psychiatric conditions benefit from varying stimulation intensities, a need the Company's scalable technology uniquely addresses.
• Safety and Accessibility: The Company's technology has the potential to offer a powerful, non-invasive alternative to costly and risk-laden procedures like deep brain stimulation (DBS) or focused ultrasound.

Mark White, CEO of Nexalin Technology, added, "This publication marks an important milestone as we continue to execute our strategic plan to bring Nexalin's DIFS technology to market. Our technology's ability to deliver deep brain stimulation non-invasively not only validates its clinical potential but also strengthens our competitive position in a rapidly expanding industry. We are confident this will drive value for patients and investors alike."

The editorial further highlights the shortcomings of traditional neuromodulation methods, emphasizing the Company's competitive advantages in safety, efficacy, and market potential. With this validation, the Company's goal is to capture a significant share of the growing neuromodulation market, aligning with broader trends in healthcare innovation and precision medicine.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: .

Forward-looking statements

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com